Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings

American Journal of Managed Care

Volumn 20, Issue 5, 2014, Pages

  Fagerness, Jesen ^a   Fonseca, Eileen ^b   Hess, Gregory P ^b,c   Scott, Rachel ^a   Gardner, Kathryn R ^a   Koffler, Michael ^a   Fava, Maurizio ^d   Perlis, Roy H ^d   Brennan, Francis X ^a   Lombard, Jay ^a  

^a Genomind LLC   (United States)

^b Symphony Health Solutions   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MENTAL PATIENT; OUTPATIENT; PERCEPTION; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHIATRY; REPLICATION STUDY; RETROSPECTIVE STUDY; CASE CONTROL STUDY; ECONOMICS; FEMALE; GENETIC SCREENING; GENETICS; HEALTH CARE DELIVERY; MALE; MENTAL DISORDERS; MIDDLE AGED; PROCEDURES; PROPENSITY SCORE; STATISTICS AND NUMERICAL DATA; UTILIZATION;

PSYCHOTROPIC AGENT;

CASE-CONTROL STUDIES; COST SAVINGS; DELIVERY OF HEALTH CARE; FEMALE; GENETIC TESTING; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; MIDDLE AGED; PHARMACOGENETICS; PROPENSITY SCORE; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 84903625870     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mental health disorder statistics: statistics related to mental health disorders. Johns Hopkins Medicine website. http://www.hopkinsmedicine.org/ healthlibrary/conditions/mental-health-disorders/mental-health-disorder- statistics-85,P00753/. Accessed February 8, 2013.
2. Insel TR. Assessing the economic costs of serious mental illness. Am J Psychiatry. 2008;165(6):663-665. (Pubitemid 351810530)
3. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatmentresistant depression on healthcare utilization and costs. J Clin Psychiatry. 2002;63(11):963-971. (Pubitemid 35388053)
4. Mathew SJ. Treatment-resistant depression: recent developments and future directions. Depress Anxiety. 2008;25(12):989-992.
5. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(suppl 6):16-22. (Pubitemid 44078108)
6. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the national comorbidity survey replication (ncs-r). JAMA. 2003;289(23):3095-3105. (Pubitemid 37432885)
7. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-459. (Pubitemid 350284935)
8. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmaco Economics. 2004;22(6):363-373. (Pubitemid 38609813)
9. Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5): 370-377.
10. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(10 suppl):1-26.
11. Chung-Feng K, Yu-Sheng F, Zhongming Z, Po-Hsiu K. Prioritization and evaluation of depression candidate genes by combining multidimensional data resources. PLoS One. 2011;6(4):18696.
12. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011; 36(2):87-113.
13. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. New Engl J Med. 2003;348(6):538-549. (Pubitemid 36159890)
14. Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73(7): 679-682.
15. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473-500.
16. Baune BT, Hohoff C, Berger K, et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology. 2008;33(4):924-932. (Pubitemid 351252697)
17. Murphy GM, Jr., Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163-1169. (Pubitemid 39463418)
18. Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology. 2009;59(4):222-226.
19. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167(7):763-772.
20. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22(4):239-258.
21. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167(7):763-772.
22. Lencz T, Robinson DG, Napolitano B, et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010;20(9):569-572.
23. Bhat S, Dao DT, Terrillion CE, et al. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol. 2012;99(1):1-14.
24. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011;43(10): 977-983.
25. Baser O. Too much ado about propensity score models? comparing methods of propensity score matching. Value Health. 2006;9(6):377-385. (Pubitemid 44511151)
26. Luo Z, Gardiner JC, Bradley CJ. Applying propensity score methods in medical research: pitfalls and prospects. MCRR. 2010;67(5):528-554.
27. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using manyto- one matching on the propensity score. Am J Epidemiol. 2010;172(9): 1092-1097.
28. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150-161.
29. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
30. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424.
31. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999; 21(6):1074-1090. (Pubitemid 29326165)
32. Woltmann EM, Valenstein M, Welsh DE, et al. Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. Psychiatr Serv. 2007;58(6):864-867. (Pubitemid 46985182)
33. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Analysis. 2007;15(3):199-236.
34. Ho DE, Imai, K, King, G, Stuart, EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Soft. 2011;42(8):1-29.
35. Whitlock MC. Combining probability from independent tests: the weighted z-method is superior to Fisher's approach. J Evol Biol. 2005; 18(5):1368-1373. (Pubitemid 41725687)
36. Rubio JM, Markowitz JC, Alegria A, et al. Epidemiology of chronic and nonchronic major depressive disorder: results from the national epidemiologic survey on alcohol and related conditions. Depress Anxiety. 2011;28(8):622-631.
37. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805-811. (Pubitemid 32577440)
38. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20(2):246-251. (Pubitemid 30202369)
39. Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Translational Psychiatry. 2013;3:e242.
40. Herbild L, Andersen SE, Werge T, Rasmussen HB, Jurgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol. 2013;113(4):266-272.
41. Stuart BC, Doshi JA, Terza JV. Assessing the impact of drug use on hospital costs. Health Serv Res. 2009;44(1):128-144.
42. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and healthcare costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699. (Pubitemid 38445514)
43. Burton WN, Chen CY, Conti DJ, Schultz AB, Edington DW. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care. 2007;13(2):105-112.